Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

125.45 USD UNCHANGED
Streaming Delayed Price Updated: 5:25 PM EST, Nov 25, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 125.45
Bid (Size) 123.29 (1)
Ask (Size) 128.82 (1)
Prev. Close 125.45
Today's Range 125.45 - 125.45
52wk Range 84.97 - 167.33
Shares Outstanding 100,522,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq Virtual Investor Conference on... 
From Business Wire News Releases
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing S
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a new framework for value-based agreements (VBAs) designed to help people with primary hyperoxaluria... 
From Business Wire News Releases

Performance

YTD
+8.50%
+8.50%
1 Month
-1.08%
-1.08%
3 Month
-5.71%
-5.71%
6 Month
-5.75%
-5.75%
1 Year
+6.71%
+6.71%

More News

Read More
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Ped
From Business Wire News Releases
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
From Business Wire News Releases
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
From Business Wire News Releases
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity
From Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Business Wire News Releases
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)
From Business Wire News Releases
Alnylam Named a Top Biopharma Employer by Science Magazine
From Business Wire News Releases
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results
From Business Wire News Releases
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.